New blood test could enable early detection of aggressive breast cancer

A research initiative at GITAM University is working to create a blood-based diagnostic test capable of detecting triple-negative breast cancer at an earlier, more treatable stage. The project, funded by the Indian Council of Medical Research (ICMR), represents an effort to address a significant gap in cancer detection capabilities for one of the most challenging forms of breast malignancy.

Triple-negative breast cancer accounts for approximately 10-15 percent of all breast cancer cases but is associated with higher mortality rates and greater aggressiveness compared to other subtypes. The disease's rapid progression and limited targeted treatment options make early detection particularly critical for improving patient survival rates.

The research methodology involves comparative analysis of blood samples collected from women diagnosed with early-stage triple-negative breast cancer alongside samples from healthy women. By identifying biomarkers or molecular signatures present in the blood of affected individuals, researchers aim to develop a non-invasive screening tool that could facilitate timely intervention.

Successful development of such a test could significantly impact cancer management in India, where breast cancer remains the most common malignancy among women. Early detection through accessible blood testing would potentially enable physicians to initiate treatment during the disease's more responsive phases, thereby improving therapeutic outcomes and survival rates across patient populations.

The GITAM project aligns with broader efforts within India's medical research community to leverage biomarker-based diagnostics for improved cancer detection and patient care.